Autoimmune drivers and protectors team science (ADAPTS)

Active Cooperative Agreement Awarded Last action

Award ID
U01AI176244
Recipient
Awarding agency
Obligated
$11,530,940

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 74% complete
Place of performance
Oklahoma City, OK 73104, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Systemic lupus erythematosus (SLE) is a heterogeneous, systemic autoimmune disease that causes significant morbidity and early mortality, especially in minority populations and in women of child-bearing age. By the time patients reach SLE classification, the majority exhibit organ/tissue damage and ongoing, aggressive inflammatory processes. Preventing SLE would reduce the risk of irreversible organ damage and treatment-related toxicities, but requires identification and validation of drivers and restraints of disease progression during this pre-/early-clinical time period. Our research groups have made important progress toward deciphering aspects of preclinical autoimmunity. A few findings include showing: autoantibodies occur in linked-subsets years before clinical disease, demonstrating humoral epitope spreading and peripheral immune dysregulation in preclinical autoimmune transition, defining immune endotypes of autoantibody positive healthy individuals, identifying activated B cell and select myeloid cell subsets preceding SLE disease flare, and establishing viral reactivation preceding SLE disease onset. Through our newly formed adapts consortium, we will address these gaps with twelve available, complementary pre-disease unique collections that span this continuum from benign autoimmunity to active SLE, which includes clinical data, questionnaire information, biospecimens, autoantibody and other experimental data from nearly 11,000 participants. A subset of the highest-risk individuals earlier in this continuum will be followed for autoimmune and clinical progression. These cross-sectional collections are augmented with longitudinal transitional cohorts which include over 400 individuals who transition to SLE with pre-disease samples and clinical data. Our investigative team members bring strengths in clinical investigation, innate immunology, cell-free nucleic acid sensing, soluble mediator characterization, multi-omic analyses, cellular immunology, immune metabolism, systems immunology, bioinformatics and strong, productive collaborations. Building on our published and new preliminary data, our adapts consortium of clinical and basic scientists will assess potentially independent or complementary mechanisms of disease progression and immune restraint by testing the roles of RNA-sensing pathways, cell-free nucleic acids, age-associated B cells and autoantibody characteristics, myeloid cell subsets, T cell lymphopenia and lymphopenia-induced proliferation, T cell immunometabolism, as well as select environmental (microbiome, virome), genomic and innate and adaptive immune responses as drivers of SLE disease. We will also validate and refine predictive models of clinical SLE disease development to inform future prevention trials and assist the field through molecular and clinical endotype identification of the preclinical time periods. Data from this integrated research program will inform targeted immune-mediated prevention trial development, selection of cellular/molecular and pathway-directed therapies, and the design of longitudinal SLE natural history or prevention studies.

Transactions

Action Obligated Date
Amendment $0
Amendment $1,288,071
Amendment $1,288,071
Amendment $1,249,430
Amendment $128,808
Amendment $128,808
Amendment $1,159,263
Amendment $1,159,263
Amendment $1,159,263
Amendment $1,323,321
Amendment $1,323,321
Original award $1,323,321
Show all 12

Subawards

Subrecipient Amount Awarded
New York Society For The Relief Of Ruptured & Crippled, Maintaining The Hospital For Special Surgery Under the direction of Dr. Robert Clancy, HSS will: 1. Provide access to biospecimens and associated clinical data from established cohorts of… $136,122
The University Of Chicago Dr. Rathmell and his laboratory will perform experiments described in Aim 4 of the application. This will include comparing immune and metabolic features of… $238,640
Vanderbilt University Medical Center Dr Ormseth and her laboratory will perform experiments indicated in Aim 1c of the application. This will include measuring human and non-human plasma small RNAs… $184,484
The Trustees Of Columbia University In The City Of New York Dr. Clancy will oversee the studies to identify overlaps and distinctions of phenotypes of the RRNL mothers and select individuals of the OMRF cohorts as… $21,571
The University Of Chicago Dr. Rathmell and his laboratory will perform experiments described in Aim 4 of the application. This will include comparing immune and metabolic features of… $206,435
Vanderbilt University Medical Center Dr. Rathmell and his laboratory will perform experiments described in Aim 4 of the application. This will include measuring immune and metabolic features of… $186,685
The Trustees Of Columbia University In The City Of New York Dr. Clancy will oversee the studies to identify overlaps and distinctions of phenotypes of the RRNL mothers and select individuals of the OMRF cohorts as… $121,816
New York University Dr. Jill Buyon at New York University Grossman School of Medicine will work with Dr. Peter Izmirly to interview patients enrolled in RRNL and STOPBLOQ, see them… $121,599
The Trustees Of Columbia University In The City Of New York Dr. Clancy will oversee the studies to identify overlaps and distinctions of phenotypes of the RRNL mothers and select individuals of the OMRF cohorts as… $139,947
New York University Dr. Jill Buyon at New York University Grossman School of Medicine will work with Dr. Peter Izmirly to interview patients enrolled in RRNL and STOPBLOQ, see them… $125,510
Vanderbilt University Medical Center Dr. Rathmell and his laboratory will perform experiments described in Aim 4 of the application. This will include measuring immune and metabolic features of… $423,320
Vanderbilt University Medical Center Dr. Rathmell and his laboratory will perform experiments described in Aim 4 of the application This will include measuring immune and metabolic features of… $423,320
Show all 12

Quick answers

Who received award U01AI176244?

U01AI176244 was awarded to Oklahoma Medical Research Foundation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 1, 2023.

How much is award U01AI176244 worth?

$11,530,940 has been obligated on U01AI176244.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login